Royalty Pharma (NASDAQ:RPRX) EVP Sells $805,200.00 in Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the company’s stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $40.26, for a total value of $805,200.00. Following the completion of the transaction, the executive vice president owned 20,000 shares of the company’s stock, valued at $805,200. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Marshall Urist also recently made the following trade(s):

• On Friday, January 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $39.52, for a total transaction of $790,400.00.
• On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $40.78, for a total transaction of $815,600.00.
• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.32, for a total transaction of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total transaction of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total transaction of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total transaction of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total value of $727,855.80.

Royalty Pharma Trading Up 0.3%

RPRX traded up $0.11 during midday trading on Monday, reaching $40.51. 5,086,791 shares of the company’s stock traded hands, compared to its average volume of 3,851,069. Royalty Pharma PLC has a 52 week low of $29.66 and a 52 week high of $41.70. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. The firm has a fifty day moving average of $39.35 and a two-hundred day moving average of $37.58. The stock has a market capitalization of $23.38 billion, a price-to-earnings ratio of 30.69, a P/E/G ratio of 1.54 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The firm had revenue of $609.29 million for the quarter, compared to analysts’ expectations of $765.01 million. On average, equities analysts anticipate that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 20th will be given a dividend of $0.235 per share. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Friday, February 20th. Royalty Pharma’s dividend payout ratio is presently 66.67%.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Nordea Investment Management AB lifted its position in shares of Royalty Pharma by 603.9% during the second quarter. Nordea Investment Management AB now owns 655,995 shares of the biopharmaceutical company’s stock worth $23,701,000 after purchasing an additional 562,799 shares during the last quarter. Watchtower Advisors LP purchased a new stake in Royalty Pharma in the 2nd quarter valued at about $3,603,000. World Investment Advisors bought a new position in Royalty Pharma in the 3rd quarter worth about $1,702,000. Financiere des Professionnels Fonds d investissement inc. purchased a new position in shares of Royalty Pharma during the third quarter worth approximately $933,000. Finally, Generali Asset Management SPA SGR increased its position in shares of Royalty Pharma by 7,752.8% during the third quarter. Generali Asset Management SPA SGR now owns 34,081 shares of the biopharmaceutical company’s stock worth $1,202,000 after acquiring an additional 33,647 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on RPRX shares. Leerink Partners set a $45.00 price target on shares of Royalty Pharma in a research report on Thursday, December 11th. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. The Goldman Sachs Group assumed coverage on shares of Royalty Pharma in a research report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price objective on the stock. Finally, Morgan Stanley decreased their price objective on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.60.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.